Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial

2009-06-25 14:07:10 -

London, June , 25, 2009

Jerusalem,  Israel  and   Lund,  Sweden,   June  25,   2009  -   Teva
Pharmaceutical Industries  Ltd.  (NASDAQ: TEVA)  and  Active  Biotech
(NASDAQ OMX  NORDIC:  ACTI)  today announced  completion  of  patient
enrollment for the  second pivotal Phase  III clinical trial,  BRAVO,
evaluating the  novel,  oral  once-daily  immunomodulating  compound,
laquinimod,  for  the   treatment  of  relapsing-remitting   multiple
sclerosis (RRMS).  BRAVO  is  a global  clinical  trial  designed  to
evaluate the efficacy, safety  and tolerability of laquinimod  versus
placebo, and to  provide risk-benefit  data for  laquinimod versus  a
currently available injectable treatment, Avonex®.

hugin.info/1002/R/1324912/311387.pdf


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.